Search results for "Usted"

showing 10 items of 114 documents

Adolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019

2022

Correction to Lancet Public Health 2022; 7: e657-69. Lancet Public Health. 2022 Dec;7(12):e992. doi: 10.1016/S2468-2667(22)00294-8. PMID: 36462522. Background: Globally, transport and unintentional injuries persist as leading preventable causes of mortality and morbidity for adolescents. We sought to report comprehensive trends in injury-related mortality and morbidity for adolescents aged 10-24 years during the past three decades. Methods: Using the Global Burden of Disease, Injuries, and Risk Factors 2019 Study, we analysed mortality and disability-adjusted life-years (DALYs) attributed to transport and unintentional injuries for adolescents in 204 countries. Burden is reported in absolut…

MaleAdolescentRJ101AdolescentsGlobal Burden of DiseaseLife ExpectancyRJ101 Child Health. Child health servicesSDG 3 - Good Health and Well-beingRA0421Risk FactorsRA0421 Public health. Hygiene. Preventive MedicineHumansMortalityChildrenInterventionsMCCUnintentional injuriesPreventionPublic Health Environmental and Occupational Health3rd-DASGBD 2019 Adolescent Transport and Unintentional Injuries Collaborators3142 Public health care science environmental and occupational healthAdolescent transportPreventable causesHealthFemaleQuality-Adjusted Life YearsInvestmentMorbidityAdolescent transport and unintentional injuries: a systematic analysis using the Global Burden of Disease Study 2019The Lancet Public Health
researchProduct

Global, regional, and national burden of stroke and its risk factors, 1990–2019 : a systematic analysis for the Global Burden of Disease Study 2019

2021

Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]…

MaleAging030204 cardiovascular system & hematologyStroke dataGUIDELINES3124 Neurology and psychiatryBody Mass IndexGlobal Burden of Disease0302 clinical medicineRA0421Risk FactorsEpidemiologyStrokesYOUNG-ADULTSPrevalence80 and overAetiology610 Medicine & healthStrokePOPULATION1103 Clinical Sciences 1109 NeurosciencesCause of deathAged 80 and overeducation.field_of_studyMortality rateIncidence (epidemiology)Incidence1. No povertyArticlesHälsovetenskaperMiddle AgedStroke typesddc:3. Good healthStrokeISCHEMIC-STROKEIncomeFemaleQuality-Adjusted Life YearsLife Sciences & BiomedicineAdultmedicine.medical_specialtyGBDPopulationClinical SciencesClinical Neurology610 Medicine & health03 medical and health sciencesClinical ResearchMIDDLE-INCOME COUNTRIESHealth SciencesmedicineHumansRisk factoreducationGBD 2019 Stroke CollaboratorsCerebral HemorrhageAgedIschemic StrokeGlobal burdenScience & TechnologyNeurology & NeurosurgeryHYPERTENSIONbusiness.industryMORTALITYPrevention3112 NeurosciencesNeurosciences1103 Clinical SciencesSERVICESSubarachnoid Hemorrhagemedicine.diseasePREVENTIONBrain DisordersGood Health and Well BeingAttributable riskHuman medicineNeurology (clinical)Neurosciences & Neurologybusiness1109 Neurosciences030217 neurology & neurosurgeryDemography2.4 Surveillance and distributionRC
researchProduct

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 2…

2018

This systematic analysis evaluates the cancer burden over time at the global and national levels measured in incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life-years.

MaleCancer ResearchIncidenceResearchHistory 20th CenturyGlobal HealthHistory 21st CenturySurvival AnalysisGlobal Burden of DiseaseOncologyOncology; Cancer ResearchNeoplasmsHumansOnline FirstFemaleQuality-Adjusted Life YearsOriginal Investigation
researchProduct

The global burden of cancer attributable to risk factors, 2010–19 : A systematic analysis for the Global Burden of Disease Study 2019

2022

Background: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. Methods: The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk-outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 20…

MaleDEATHSDALY cancer risk factorsMedizinsystematic analysisGlobal HealthRisk AssessmentCancer preventionGlobal Burden of DiseaseRC0254Risk-attributable cancer deathsSDG 3 - Good Health and Well-beingRA0421Risk FactorsRA0421 Public health. Hygiene. Preventive MedicineQuality-Adjusted Life YearNeoplasmscancerHumansGlobal Burden of Disease StudyUKMedicine(all)MCCRC0254 Neoplasms. Tumors. Oncology (including Cancer)Risk FactorSmokingCOVID-193rd-DASGeneral MedicineDisability-adjusted life-yearsSOCIAL DETERMINANTSRisk assessmentsrisk factorCardiovascular and Metabolic Diseases3121 General medicine internal medicine and other clinical medicineOBESITYCancer burden/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingNeoplasmFemaleLIFE-STYLEQuality-Adjusted Life YearsHEALTHRAHumanRC
researchProduct

Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study …

2020

Publisher's version (útgefin grein)

MaleLife expectancyDisability-Adjusted Life YearDiseasesDiseasecommunicable diseasesystematic analysisGlobal Burden of Disease0302 clinical medicine80 and overMedicine10. No inequalityChild11 Medical and Health SciencesinjuriesAged 80 and overeducation.field_of_studySjúkdómarDEMENTIAFALLSGeneral MedicineForvarnir3. Good healthChild PreschoolHumanGBDPopulation health03 medical and health sciencesSDG 3 - Good Health and Well-beingHumansGlobal Burden of Disease StudyeducationAgedSpatial AnalysisGlobal burdenDisabilityPreventionDISABILITYInfantSpatial AnalysiMortality rateGlobal Burden of Disease Diseases Injuries Systematic analysisPREVENTIONYears of potential life lostRisk factorsDisease studyGBD; communicable disease; injuries;ITC-ISI-JOURNAL-ARTICLELife expectancyRISK-FACTORSClinical MedicineRADemographyFötlunDánartíðniÁhættuþættir030204 cardiovascular system & hematologyRisk FactorsCause of DeathGlobal health030212 general & internal medicineMortality ratePopulation health1. No povertyDisability-Adjusted Life YearsPublic Health Global Health Social Medicine and EpidemiologyMiddle Aged3142 Public health care science environmental and occupational healthAdolescent; Adult; Age Distribution; Aged; Aged 80 and over; Cause of Death; Child; Child Preschool; Disability-Adjusted Life Years; Female; Global Burden of Disease; Humans; Infant; Infant Newborn; Male; Middle Aged; Risk Factors; Spatial Analysis; Young Adult/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingLýðheilsaFemaleCLINICAL-TRIALSAdultAdolescentPopulationGlobal healthSettore MED/01 - Statistica MedicadiseasesITC-HYBRIDYoung AdultHeilbrigðisvísindiAge DistributionGeneral & Internal MedicineMortalityPreschoolDisease burdenbusiness.industryRisk FactorKlinisk medicinInfant NewbornNewborn//purl.org/pe-repo/ocde/ford#3.02.00 [https]Folkhälsovetenskap global hälsa socialmedicin och epidemiologiÁverkarSystematic analysisNAbusiness
researchProduct

Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

2014

Abstract Background We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy. Methods Cost-effectiveness analysis performed according to data from the available published literature. The target population was composed of untreated Caucasian patients, aged 50 years, with genotype 1 chronic hepatitis C, and these were evaluated over a lifetime horizon by Markov model. The study was carried out from the perspective of the Italian Nati…

MaleNational Health ProgramsCost effectivenessCost-Benefit AnalysisHepacivirusNational Health ProgramHepacivirusPharmacologyPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundQuality-Adjusted Life YearMedicineSettore SECS-S/05 - Statistica SocialeMultivariate AnalysiBoceprevirSettore MED/12 - GastroenterologiabiologyMedicine (all)GastroenterologyMiddle AgedRecombinant ProteinMarkov ChainsRecombinant ProteinsModels EconomicTreatment OutcomeItalyDrug Therapy CombinationFemaleQuality-Adjusted Life YearsSettore SECS-S/01 - StatisticaViral loadHumanmedicine.medical_specialtyGenotypeProlineAlpha interferonInterferon alpha-2Antiviral AgentsInternal medicineBoceprevirRibavirinHumansCost-Benefit AnalysiAntiviral AgentHepaciviruPeg-interferonHepatologybusiness.industryRibavirinInterferon-alphaHepatologyHepatitis C ChronicMarkov Chainbiology.organism_classificationQuality-adjusted life yearchemistryCost-effectiveneMultivariate AnalysisQuality of LifeCost-effectivenessbusiness
researchProduct

Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma

2013

The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. We created a Markov Decision Model to evaluate, in a hypothetical cohort of Caucasian male patients, aged 67 years with Barcelona Clinic Liver Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, well compensated cirrhosis, and with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG), the cost-effectiveness of the following strategies: (1) full or dose-adjusted sorafenib for …

MaleNiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularCost effectivenessCost-Benefit AnalysisSettore MED/12 - GASTROENTEROLOGIAAged; Antineoplastic Agents; Carcinoma Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality-Adjusted Life YearsAntineoplastic AgentsKaplan-Meier EstimateDrug CostsInternal medicinemedicineHumansProspective StudiesProspective cohort studyneoplasmsSurvival rateAgedHepatologyPerformance statusbusiness.industryPhenylurea CompoundsLiver NeoplasmsCarcinomaHepatocellular carcinoma sorafenib ICER cost-effectivenessHepatocellularSorafenibmedicine.diseaseMarkov Chainsdigestive system diseasesSurgeryQuality-adjusted life yearHepatocellular carcinomaMultivariate AnalysisQuality-Adjusted Life YearsbusinessLiver cancermedicine.drugHepatology
researchProduct

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-s…

2010

Abstract Background The objective of this study was to conduct a cost-effectiveness evaluation of pemetrexed compared to docetaxel in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) for patients with predominantly non-squamous histology in the Spanish healthcare setting. Methods A Markov model was designed consisting of stable, responsive, progressive disease and death states. Patients could also experience adverse events as long as they received chemotherapy. Clinical inputs were based on an analysis of a phase III clinical trial that identified a statistically significant improvement in overall survival for non-squamous patients treated with pemetrexed compared …

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyGuanineLung NeoplasmsCost-Benefit AnalysisPopulationDocetaxelPemetrexedlcsh:RC254-282Disease-Free SurvivalGlutamatesSurgical oncologyCarcinoma Non-Small-Cell LungCell Line TumorInternal medicineGeneticsCarcinomamedicineHumanseducationLung cancerneoplasmseducation.field_of_studybusiness.industryCarcinomaHistologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMarkov Chainsrespiratory tract diseasesQuality-adjusted life yearTreatment OutcomePemetrexedOncologyDocetaxelSpainDisease ProgressionQuality of LifeFemaleTaxoidsQuality-Adjusted Life YearsbusinessResearch Articlemedicine.drugBMC Cancer
researchProduct

Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015

2017

IMPORTANCE Elevated systolic blood (SBP) pressure is a leading global health risk. Quantifying the levels of SBP is important to guide prevention policies and interventions. OBJECTIVE To estimate the association between SBP of at least 110 to 115 mm Hg and SBP of 140 mm Hg or higher and the burden of different causes of death and disability by age and sex for 195 countries and territories, 1990-2015. DESIGN A comparative risk assessment of health loss related to SBP. Estimated distribution of SBP was based on 844 studies from 154 countries (published 1980-2015) of 8.69 million participants. Spatiotemporal Gaussian process regression was used to generate estimates of mean SBP and adjusted va…

MalePediatricsMyocardial IschemiaNormal DistributionPROGRESSIONBlood Pressure030204 cardiovascular system & hematologyGlobal Health0302 clinical medicineCause of DeathPrevalence030212 general & internal medicineStrokeCause of deathAged 80 and overMortality rateUncertaintyGeneral Medicine11 Medical And Health SciencesMiddle AgedStrokeCARDIOVASCULAR-DISEASEHypertensionCardiologyBlood pressureHipertensióFemaleQuality-Adjusted Life YearsARTERIAL STIFFNESSLife Sciences & BiomedicineIntracranial HemorrhagesMonte Carlo MethodAdultmedicine.medical_specialtySystolePressió sanguíniaRisk Assessment03 medical and health sciencesMedicine General & InternalAGEAge DistributionInternal medicineGeneral & Internal MedicinemedicineDisability-adjusted life yearHumansCORONARY-HEART-DISEASESystoleRenal Insufficiency ChronicSex DistributionMETAANALYSISAgedScience & Technologybusiness.industryMORTALITYKIDNEY-DISEASEmedicine.diseaseHealth SurveysQuality-adjusted life yearBlood pressureArterial stiffnessRISK-FACTORSbusiness
researchProduct

Estimating global injuries morbidity and mortality

2020

Background. While there is a long history of measuring death and disability from injuries, modern research methods must account for the wide spectrum of disability that can occur in an injury, and must provide estimates with sufficient demographic, geographical and temporal detail to be useful for policy makers. The Global Burden of Disease (GBD) 2017 study used methods to provide highly detailed estimates of global injury burden that meet these criteria. Methods. In this study, we report and discuss the methods used in GBD 2017 for injury morbidity and mortality burden estimation. In summary, these methods included estimating cause-specific mortality for every cause of injury, and then est…

MalePopulations/contexts1106 Human Movement and Sports SciencesGlobal injuriespopulation030204 cardiovascular system & hematologyGlobal HealthcontextscontextGlobal Burden of Disease0302 clinical medicineQuality-Adjusted Life YearGlobal health1506030212 general & internal medicineOriginal ResearchDatapopulations/contextsIncidence (epidemiology)Incidencemethodology3142 Public health care science environmental and occupational healthPeer reviewFemalePublic HealthTERRITORIESQuality-Adjusted Life Yearsdescriptive epidemiologyHumanDisabilities195 COUNTRIESstatistical issue1117 Public Health and Health Services03 medical and health sciencesAGELife ExpectancyEnvironmental healthInjury preventionSYSTEMATIC ANALYSISstatistical issuesHumansMortalityEstimationSEX-SPECIFIC MORTALITYDISABILITYPublic Health Environmental and Occupational Healthpopulations; contexts; methodology; descriptive epidemiology; statistical issues; Female; Humans; Incidence; Life Expectancy; Male; Morbidity; Quality-Adjusted Life Years; Global Burden of Disease; Global Health; Wounds and Injuriespopulations1106 Human Movement and Sports Sciences 1117 Public Health and Health Services 1701 PsychologyQuality-adjusted life yearYears of potential life lost1701 PsychologyLife expectancyEstimatesWounds and InjuriesHuman medicineMorbiditypopulations/contextInjury prevention
researchProduct